Welcome to our dedicated page for AstraZeneca PLC news (Ticker: $AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AstraZeneca PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AstraZeneca PLC's position in the market.
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU gains accelerated approval in the US for HER2-positive solid tumors, marking a significant milestone in targeted cancer treatment. The approval is based on positive response rates and duration of response in Phase II trials, leading to inclusion in NCCN Guidelines®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
-
Rhea-AI Summary
AstraZeneca's IMFINZI shows survival benefit in Phase III trial for -stage small cell lung cancer, marking a breakthrough in treatment. Positive results in OS and PFS with no new safety signals identified. IMFINZI continues to lead in lung cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
-
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of advanced nonsquamous non-small cell lung cancer and HR positive, HER2 negative breast cancer. The BLA is based on positive results from the TROPION-Breast01 phase 3 trial, with a PDUFA date set for January 29, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
Rhea-AI Summary
VOYDEYA (danicopan) has been approved in the US as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The approval was based on positive results from the pivotal ALPHA Phase III trial, showing efficacy in addressing EVH. VOYDEYA met primary and secondary endpoints, was well-tolerated, and received Breakthrough Therapy designation and PRIME status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
ULTOMIRIS, the first long-acting C5 complement inhibitor, receives US FDA approval for treating AQP4 Ab+ NMOSD, showing a 98.6% relapse risk reduction in the CHAMPION-NMOSD trial. NMOSD is a rare autoimmune disease affecting the CNS, with about 6,000 diagnosed cases in the US. The safety profile of ULTOMIRIS remains consistent with previous studies, with COVID-19, headache, back pain, arthralgia, and urinary tract infection being the most common adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
-
Rhea-AI Summary
AstraZeneca acquires Fusion Pharmaceuticals Inc., a clinical-stage company developing radioconjugates for cancer treatment. The acquisition aims to enhance AstraZeneca's oncology portfolio with a focus on prostate cancer treatment. The deal includes a transaction value of approximately $2.4bn, bringing new expertise and capabilities to AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
Rhea-AI Summary
GRAIL, in collaboration with AstraZeneca, will test samples from Japanese participants using its risk classification test on the Methylation Platform for lung adenocarcinoma. The study aims to show results within 10 days without tumor tissue, supporting future pharmaceutical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
AstraZeneca expands savings programs for US inhaled respiratory portfolio, offering eligible patients to pay no more than $35 per month for medicines. The company aims to make inhalers more affordable for vulnerable patients with asthma and COPD. Starting June 1, 2024, patients can access this program for various respiratory medicines, including SYMBICORT. AstraZeneca emphasizes its commitment to addressing access and affordability barriers for patients with respiratory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
AstraZeneca initiates Phase III trial for BREZTRI AEROSPHERE to reduce severe cardiopulmonary outcomes in COPD patients. The ATHLOS trial also begins to compare BGF with other therapies on cardiopulmonary parameters. COPD's impact on global population and the increased risk of cardiopulmonary events are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan shows significant improvement in progression-free survival in lung and breast cancer. European Medicines Agency validates marketing authorization applications for the drug in two types of cancer, based on phase 3 trial results. The drug aims to replace conventional chemotherapy in the treatment of multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
AstraZeneca PLC
Nasdaq:AZN
AZN Rankings
AZN Stock Data
240.63B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Cambridge
About AZN
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.